Direkt zum Inhalt
Merck

855810P

Avanti

26:0 Lyso PC

1-hexacosanoyl-2-hydroxy-sn-glycero-3-phosphocholine, powder

Synonym(e):

1-hexacosanoyl-sn-glycero-3-phosphocholine; PC(26:0/0:0)

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C34H70NO7P
CAS-Nummer:
Molekulargewicht:
635.90
MDL-Nummer:
UNSPSC-Code:
51191904
NACRES:
NA.25

Assay

>99% (LPC; may contain up to 10% of the 2-LPC isomer, TLC)

Form

powder

Verpackung

pkg of 1 × 10 mg (855810P-10mg)
pkg of 1 × 25 mg (855810P-25mg)
pkg of 1 × 5 mg (855810P-5mg)

Hersteller/Markenname

Avanti Research - A Croda Brand 855810P

Versandbedingung

dry ice

Lagertemp.

−20°C

Allgemeine Beschreibung

Lysophosphatidylcholine (LPC) is a bioactive proinflammatory lipid, which has a choline group at its polar head. It is produced by pathological response.

Anwendung

26:0 Lyso PC has been used as an internal standard for C26:0-lysophosphatidylcholine (LPC) extraction.

Biochem./physiol. Wirkung

Lysophosphatidylcholine (LPC) induces many second messengers including, protein kinase C, extracellular-signal-regulated kinases and protein tyrosine kinases. It alters various biological functions in different cell types, including endothelial cells, smooth muscle cells, monocytes, macrophages and T-cells. LPC is linked to atherosclerosis and inflammatory diseases.

Verpackung

5 mL Amber Glass Screw Cap Vial (855810P-10mg)
5 mL Amber Glass Screw Cap Vial (855810P-25mg)
5 mL Amber Glass Screw Cap Vial (855810P-5mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Lagerklassenschlüssel

11 - Combustible Solids


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Xinying Hong et al.
Genetics in medicine : official journal of the American College of Medical Genetics (2020-04-21)
To develop a multiplexed assay for the newborn screening of lysosomal storage disorders and additional inborn errors in a flexible, comprehensive, and affordable manner to keep up with the expansion of the newborn screening panel. Ultraperformance liquid chromatography-tandem mass spectrometry
A thyroid hormone-based strategy for correcting the biochemical abnormality in X-linked adrenoleukodystrophy
Hartley MD, et al.
Endocrinology, 158(5), 1328-1338 (2017)
Analysis of phospholipid species in rat peritoneal surface layer by liquid chromatography/electrospray ionization ion-trap mass spectrometry
Gao F, et al.
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1761(7), 667-676 (2006)
Kelsey B Law et al.
Autophagy, 13(5), 868-884 (2017-05-20)
Peroxisome biogenesis disorders (PBDs) are metabolic disorders caused by the loss of peroxisomes. The majority of PBDs result from mutation in one of 3 genes that encode for the peroxisomal AAA ATPase complex (AAA-complex) required for cycling PEX5 for peroxisomal
Role of lysophosphatidylcholine (LPC) in atherosclerosis
Matsumoto T, et al.
Current Medicinal Chemistry, 14(30), 3209-3220 (2007)

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.